Difficulties in the diagnosis of Hb S/Beta thalassemia: Really a mild disease?
Abstract
OBJECTIVE: HbS/β cases having clinical, hematologic and electrophoretic similarities cannot be sufficiently distinguished from sickle cell anemia cases, and are misdiagnosed as sickle cell anemia. This study will investigate the congruence between the HPLC thalassemia scanning tests and the laboratory findings in comparison with the DNA sequence analysis results of the patients diagnosed with SCA between 2016 and 2020. This study also aims to indicate the current status to accurately diagnose sickle cell anemia and HbS/β in the light of hematologic, electrophoretic and molecular studies.
MATERIAL METHOD: Fourteen patients who were diagnosed with SCA in hospitals at different cities in Turkey and followed by the Thalassemia Diagnosis, Treatment and Research Center, Muğla Sıtkı Koçman University were included in this retrospective study. The socio demographic characteristics, hemogram, hemoglobin variant analysis results and DNA chain analysis results of the patients were taken from the database of the center and then examined. The informed consents were taken from the patients. The patients were administered a survey containing questions about transfusion history and diagnostic awareness.
The Beta-Thalassemia mutations were analyzed using DNA sequencer (Dade Behring, Germany) based on the Sanger method.
RESULTS: According to the DNA sequence analysis results of these patients diagnosed with SCA in hospitals in different cities of Turkey: Of 14 patients, 8 had Hb S/β0 and Hb S/β+ and one had Hb S carrier, and one had Hb-O, and three had SCA. The patient with HbS carrier status also contains three additional mutations all of which are heterozygous. We discovered that although two of three mutations, which are c.315+16G>C and c.316-185C>T, are previously reported as benign, at least one of the two mentioned mutations, when combined with Hb S, causes transfusion-dependent Hb S/β.
CONCLUSION: Briefly, HbSS and HbS/β thalassemia genotypes cannot be definitely characterized by electrophoretic and hematologic data, resulting in misdiagnosis. c.315+16G>C and c.316-185C>T, are previously reported as benign, at least one of the two mentioned mutations, when combined with Hb S, causes transfusion-dependent Hb S/β.
In undeveloped or some developing countries, molecular diagnosis methods and genetic analyses cannot be used. If mutation analyses could be performed, then such differential diagnosis errors would reduce. However, if mutation analysis cannot be performed, other methods such as HPLC, capillary electrophoresis absolutely be sought to have insight into the parental carriage status.
References
Copyright © 2020, StatPearls Publishing LLC.; 2020.
2. Piel FB, Hay SI, Gupta S, Weatherall DJ, Williams TN. Global burden of sickle cell anaemia in children under five, 2010-2050: modelling based on demographics, excess mortality, and interventions. PLoS medicine. 2013;10(7):e1001484.
3. Hazzazi AA, Ageeli MH, Alfaqih AM, Jaafari AA, Malhan HM, Bakkar MM. Epidemiology and characteristics of sickle cell patients admitted to hospitals in Jazan region, Saudi Arabia. Journal of Applied Hematology. 2020;11(1):10.
4. Maakaron JE, Besa E. Sickle cell anemia. Medscape Reference [software]. 2013.
5. Bain BJ. Haemoglobinopathy diagnosis: John Wiley & Sons; 2020.
6. Thein SL. Molecular basis of β thalassemia and potential therapeutic targets. Blood Cells, Molecules, and Diseases. 2018;70:54-65.
7. Derneği TH. Eritrosit Hastalıkları Ve Hemoglobin Bozuklukları - Orak Hücre Anemisi Tanı ve Tedavi Kılavuzu. Ulusal Tanı Ve Tedavi Kılavuzu 2019;1.1:52.
8. Belisário AR, Carneiro-Proietti AB, Sabino EC, Araújo A, Loureiro P, Máximo C, et al. Hb S/β-Thalassemia in the REDS-III Brazil Sickle Cell Disease Cohort: Clinical, Laboratory and Molecular Characteristics. Hemoglobin. 2020:1-9.
9. Saraf SL, Molokie RE, Nouraie M, Sable CA, Luchtman-Jones L, Ensing GJ, et al. Differences in the clinical and genotypic presentation of sickle cell disease around the world. Paediatric respiratory reviews. 2014;15(1):4-12.
10. Figueiredo MS. The compound state: Hb S/beta-thalassemia. Revista brasileira de hematologia e hemoterapia. 2015;37(3):150-2.
11. Rees DC, Gibson JS. Biomarkers in sickle cell disease. British journal of haematology. 2012;156(4):433-45.
12. Notarangelo LD, Agostini A, Casale M, Samperi P, Arcioni F, Gorello P, et al. HbS/β+ thalassemia: Really a mild disease? A National survey from the AIEOP Sickle Cell Disease Study Group with genotype-phenotype correlation. Eur J Haematol. 2020;104(3):214-22.
13. Derneği TH. Eritrosit Hastalıkları Ve Hemoglobin Bozuklukları - Orak Hücre Anemisi Tanı ve Tedavi Kılavuzu Ulusal Tanı Ve Tedavi Kılavuzu 2019;1.1:52.
14. Christopher McKinney M, Rachelle Nuss, MD, , Kathryn L. Hassell M. Sickle Cell Disease. 2017.
15. Giardine B BJ, Viennas E, Pavlidis C, Moradkhani K, Joly P, Bartsakoulia M, Riemer C, Miller W, Tzimas G, Wajcman H, Hardison RC, Patrinos GP. Updates of the HbVar database of human hemoglobin variants and thalassemia mutations. Nucleic Acids Res. 2014 Jan;42 (Database issue):D1063-9.
16. Aslam AF, Dipillo F, Aslam AKJTAjotms. Fatal splenic sequestration crisis with multiorgan failure in an adult woman with sickle cell-beta+ thalassemia. 2005;329(3):141-3.
17. Elaine M. Keohane CNOaJMW. Rodak's Hematology Clinical Principles and Applications. Book • 6th Edition • 2020
18. Al. TBÖE. "Ülkemizde İzlenen Orak Hücre-Beta Talasemi Olgularının Çok Merkezli Değerlendirilmesi: TPHD Hemoglobinopati Çalışma Grubu Sonuçları," 12. Ulusal Pediatrik Hematoloji Kongresi , Konya, Turkey. 2019: 92-3.
19. Benites BD, Bastos SO, Baldanzi G, dos Santos AdO, Ramos CD, Costa FF, et al. Sickle cell/β-thalassemia: comparison of Sβ0 and Sβ+ Brazilian patients followed at a single institution. Hematology. 2016; 21: 623-9.
20. Bender M. Sickle Cell Disease. 2003 Sep 15 [updated 2017 Aug 17]. GeneReviews®[Internet] Seattle (WA): University of Washington, Seattle. 2017.
21. DeBaun M, Jordan L, King A, Schatz J, Vichinsky E, Fox C, et al. American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults. Blood advances. 2020; 4: 1554-88.
22. Notarangelo LD, Agostini A, Casale M, Samperi P, Arcioni F, Gorello P, et al. HbS/β+ thalassemia: Really a mild disease? A National survey from the AIEOP Sickle Cell Disease Study Group with genotype‐phenotype correlation. European Journal of Haematology. 2020; 104: 214-22.
23. Belisário AR, Sales RR, Viana MB. Very mild forms of Hb S/beta+-thalassemia in Brazilian children. Revista Brasileira de Hematologia e Hemoterapia. 2015; 37: 198-201.
24. Belisário AR, Carneiro-Proietti AB, Sabino EC, Araújo A, Loureiro P, Máximo C, et al. Hb S/β-Thalassemia in the REDS-III Brazil Sickle Cell Disease Cohort: Clinical, Laboratory and Molecular Characteristics. 2020: 1-9.
25. Dawling S.
26. Phylipsen M, Gallivan M, Arkesteijn S, Harteveld C, Giordano P. Occurrence of common and rare δ‐globin gene defects in two multiethnic populations: thirteen new mutations and the significance of δ‐globin gene defects in β‐thalassemia diagnostics. International journal of laboratory hematology. 2011; 33: 85-91.
27. Çağla Eröz2 FMA, Volkan Karakuş1. Orak hücreli anemiden beta talasemi intermediaya: kayıtlı her tanı sorgulanmaya muhtaçtır. Ulusal Hematoloji Kongresi. 2017; 43: 267.
28. Edo-Osagie E, Enofe I, Hakeem H, Rai M, Adomako E, Tismenetsky M, et al. Splenic sequestration crisis as an index manifestation of heterozygous hemoglobinopathy in an adult. 2019;2019(7):omz069.
29. Ashorobi D, Bhatt R. Bone Marrow Transplantation In Sickle Cell Disease. StatPearls [Internet]: StatPearls Publishing; 2019.
30. Al-Salem AH, Qaisaruddin S, Nasserallah Z, Al Dabbous I, Al Jam'a AJTAjos. Splenectomy in patients with sickle-cell disease. 1996; 172: 254-8.
31. Yadav R, Lazarus M, Ghanghoria P, Singh M, Gupta RB, Kumar S, et al. Sickle cell disease in Madhya Pradesh, Central India: A comparison of clinical profile of sickle cell homozygote vs. sickle-beta thalassaemia individuals. 2016; 21: 558-63.
Copyright (c) 2021 Süheyl UCUCU
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.